David Lebwohl - Sep 21, 2021 Form 4 Insider Report for Intellia Therapeutics, Inc. (NTLA)

Role
EVP, Chief Medical Officer
Signature
/s/James Basta, Attorney-in-fact
Stock symbol
NTLA
Transactions as of
Sep 21, 2021
Transactions value $
-$329,256
Form type
4
Date filed
9/23/2021, 05:48 PM
Previous filing
Sep 1, 2021
Next filing
Sep 27, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NTLA Common Stock Options Exercise $30.3K +2.4K +303.41% $12.62 3.19K Sep 21, 2021 Direct
transaction NTLA Common Stock Sale -$360K -2.4K -75.21% $149.81 791 Sep 21, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NTLA Stock Option (right to buy) Options Exercise $0 -2.4K -1.23% $0.00 193K Sep 21, 2021 Common Stock 2.4K $12.62 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
F2 The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 66,666 shares as of September 21, 2021.